37 results about "Anti-Rabies virus IgG" patented technology

A novel chimeric protein of rabies virus designed to express a chimeric G protein at a high level in transgenic plants. A gene was also designed and chemically synthesised to encode the chimeric G protein and expressed at high level in plant tissue. The gene was expressed in transgenic tobacco plants to examine its therapeutic efficacy against infection by rabies virus. The chimeric G protein was enriched in plant membranes. The BalbC mice were immunised with the plant leaf expressed G-protein. Plant derived chimeric G protein elicited higher immune response as compared to the commercial vaccine. The mice displayed protective immunity when they were challenged with live virus. Chimeric G protein expressed at high level in plant leaves was demonstrated to function as a commercially valuable subunit vaccine against rabies virus infection.

The invention discloses an anti-rabies virus monoclonal antibody and a preparation method and an application, belonging to the field of biomedicine and particularly relating to the preparation of a monoclonal antibody capable of identifying rabies virus and the application. The monoclonal antibody of the invention is screened by indirect Enzyme-linked immunosorbent assay (ELISA), and specificity and affinity thereof combined with antigen are identified by methods such as polyacrylamide gel electrophoresis analysis, speckle ELISA, immunoblot analysis and the like. The anti-rabies virus monoclonal antibody of the invention can be applied in multiple testing methods of antigen of rabies virus and can be also applied in the preparation of rabies virus detecting kit. The anti-rabies virus monoclonal antibody is secreted by anti-rabies virus monoclonal antibody hybridoma cell strain 2C5 with the preservation number being CGMCC No.3014.

The invention aims at providing a rabies virus resistant neutralizing antibody, and particularly provides a humanized or completely humanized monoclonal antibody to meet the requirement for clinically diagnosing and / or treating rabies. A phage antibody library is prepared by adopting a phage antibody library technology and taking 32 parts of high-potency healthy human peripheral blood inoculated with rabies vaccines as a raw material; 7 ELISA positive antibodies are obtained through three rounds of screening from the phage antibody library; and furthermore, the neutralizing activity of the 7 ELISA positive antibodies is measured through an RFFIT method, wherein four ELISA positive antibodies, namely R5, R7, R8 and R9, have higher neutralizing activity in all. The rabies virus resistant neutralizing antibody with high affinity, which is provided by the invention, can be used for substituting ERIG and HRIG to carry out active and / or passive immune therapy on rabies virus seriously-exposed persons.

The invention relates to the technical field of biomedical engineering, and discloses a method for screening and verifying neutralizing antibodies against rabies virus from a phage antibody library, including A, culturing monoclonal phage antibodies, and taking the culture supernatant; B, qualitative analysis : The culture supernatant in step A was placed in a 96-well plate, followed by DMEM medium and neutralizing virus neutralization, BSR cell suspension culture, pre-cooled acetone fixation, and diluted FITC-labeled anti- Co-incubation with rabies virus nucleoprotein antibody, select clones that can significantly inhibit virus infection and sequence them, eliminate repetitive sequences, and initially obtain anti-rabies virus antibody sequences with different neutralizing activities; C. Quantitative analysis: select different sequences with neutralizing activities Each clone of the phage antibody particles was re-prepared, purified and diluted to a certain number of times, and the in vitro neutralization activity was determined by RFFIT method; and D, the transient expression and activity analysis of the whole molecule antibody.